Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T56365
(Former ID: TTDC00135)
|
||||
Target Name |
B-lymphocyte surface antigen B4 (CD19)
|
||||
Synonyms |
T-cell surface antigen Leu-12; Leu-12; Differentiation antigen CD19; B-lymphocyte antigen CD19
|
||||
Gene Name |
CD19
|
||||
Target Type |
Successful target
|
[1] | |||
Disease | [+] 2 Target-related Diseases | + | |||
1 | Diffuse large B-cell lymphoma [ICD-11: 2A81] | ||||
2 | Mature B-cell lymphoma [ICD-11: 2A85] | ||||
Function |
Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. Required for normal B cell differentiation and proliferation in response to antigen challenges. Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge. Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes.
|
||||
BioChemical Class |
Immunoglobulin
|
||||
UniProt ID | |||||
Sequence |
MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKP
FLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGE LFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSL NQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMW VMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYL IFCLCSLVGILHLQRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSG LGRAQRWAAGLGGTAPSYGNPSSDVQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEF YENDSNLGQDQLSQDGSGYENPEDEPLGPEDEDSFSNAESYENEDEELTQPVARTMDFLS PHGSAWDPSREATSLGSQSYEDMRGILYAAPQLRSIRGQPGPNHEEDADSYENMDNPDGP DPAWGGGGRMGTWSTR |
||||
Drugs and Modes of Action | |||||
Approved Drug(s) | [+] 3 Approved Drugs | + | |||
1 | Axicabtagene ciloleucel | Drug Info | Approved | Diffuse large B-cell lymphoma | [2] |
2 | Blinatumomab | Drug Info | Approved | Acute lymphoblastic leukaemia | [3], [4] |
3 | Tisagenlecleucel | Drug Info | Approved | Acute lymphoblastic leukaemia | [2] |
Clinical Trial Drug(s) | [+] 162 Clinical Trial Drugs | + | |||
1 | CART-19 | Drug Info | Phase 2/3 | Acute lymphoblastic leukaemia | [5] |
2 | CD19 CAR T cells | Drug Info | Phase 2/3 | Acute lymphoblastic leukaemia | [6] |
3 | MOR-208 | Drug Info | Phase 2/3 | Diffuse large B-cell lymphoma | [7], [8], [9] |
4 | CAR-T cells targeting CD19 | Drug Info | Phase 2 | Non-hodgkin lymphoma | [10] |
5 | CART 19 | Drug Info | Phase 2 | Acute lymphoblastic leukaemia | [11], [12] |
6 | CART-19 | Drug Info | Phase 2 | Non-hodgkin lymphoma | [13] |
7 | CART-19 cells | Drug Info | Phase 2 | Multiple myeloma | [14] |
8 | CD19 CAR T cells | Drug Info | Phase 2 | B-cell chronic lymphocytic leukaemia | [15] |
9 | CD19-targeting CAR T cells | Drug Info | Phase 2 | B-cell lymphoma | [16], [17] |
10 | Coltuximab ravtansine | Drug Info | Phase 2 | Diffuse large B-cell lymphoma | [8] |
11 | CTL019 | Drug Info | Phase 2 | Chronic lymphocytic leukaemia | [18] |
12 | CTL019 | Drug Info | Phase 2 | Diffuse large B-cell lymphoma | [18], [19] |
13 | Inebilizumab | Drug Info | Phase 2 | Neuromyelitis optica | [20] |
14 | JCAR015 | Drug Info | Phase 2 | B-cell lymphoma | [21] |
15 | JCAR015 | Drug Info | Phase 2 | Acute lymphoblastic leukaemia | [21] |
16 | JCAR017 | Drug Info | Phase 2 | Central nervous system lymphoma | [22] |
17 | KYMRIAH | Drug Info | Phase 2 | Acute lymphoblastic leukaemia | [23] |
18 | MB-CART19.1 | Drug Info | Phase 2 | Precursor B-lymphoblastic neoplasm | [24] |
19 | MDX-1342 | Drug Info | Phase 2 | leukaemia | [25] |
20 | MEDI-551 | Drug Info | Phase 2 | Encephalopathy | [7] |
21 | SAR-3419 | Drug Info | Phase 2 | Non-hodgkin lymphoma | [26] |
22 | XLCART001 | Drug Info | Phase 2 | B-cell lymphoma | [27] |
23 | Xmab 5871 | Drug Info | Phase 2 | Autoimmune diabetes | [28] |
24 | YESCARTA | Drug Info | Phase 2 | Diffuse large B-cell lymphoma | [23] |
25 | 4SCAR19 and 4SCAR123 | Drug Info | Phase 1/2 | B-cell lymphoma | [29] |
26 | 4SCAR19 and 4SCAR20 | Drug Info | Phase 1/2 | B-cell lymphoma | [29] |
27 | 4SCAR19 and 4SCAR22 | Drug Info | Phase 1/2 | B-cell lymphoma | [29] |
28 | 4SCAR19 and 4SCAR30 | Drug Info | Phase 1/2 | B-cell lymphoma | [29] |
29 | 4SCAR19 and 4SCAR38 | Drug Info | Phase 1/2 | B-cell lymphoma | [29] |
30 | 4SCAR19 and 4SCAR70 | Drug Info | Phase 1/2 | B-cell lymphoma | [29] |
31 | 4SCAR19 cells | Drug Info | Phase 1/2 | B-cell lymphoma | [30] |
32 | 4SCAR19/22 T cells | Drug Info | Phase 1/2 | B-cell lymphoma | [31] |
33 | Anti-CD19 and Anti-CD20 CAR-T Cells | Drug Info | Phase 1/2 | B-cell lymphoma | [32] |
34 | Anti-CD19 CAR T cells | Drug Info | Phase 1/2 | B-cell lymphoma | [33], [34] |
35 | Anti-CD19 CAR transduced T cells | Drug Info | Phase 1/2 | Acute lymphocytic leukaemia | [35] |
36 | Anti-CD19 CAR-T | Drug Info | Phase 1/2 | Haematopoietic/lymphoid cancer | [36] |
37 | Anti-CD19 CAR-T cells | Drug Info | Phase 1/2 | Acute lymphocytic leukaemia | [37] |
38 | Anti-CD19 CAR-T cells | Drug Info | Phase 1/2 | leukaemia | [38] |
39 | Anti-CD19 CAR-T cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [39], [40] |
40 | Anti-CD19 CAR-T cells | Drug Info | Phase 1/2 | B-cell chronic lymphocytic leukaemia | [41] |
41 | Anti-CD19-CAR PBL | Drug Info | Phase 1/2 | Mantle cell lymphoma | [42] |
42 | Anti-CD19-CAR vector-transduced T cells | Drug Info | Phase 1/2 | Mantle cell lymphoma | [43], [44] |
43 | Anti-CD19-CAR-T cells | Drug Info | Phase 1/2 | leukaemia | [45] |
44 | Anti-CD19/22-CAR vector-transduced T cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [46] |
45 | Anti-CD20 CAR-T cells | Drug Info | Phase 1/2 | Diffuse large B-cell lymphoma | [47] |
46 | AUTO3 | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [48] |
47 | Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [49] |
48 | Autologous CD19-targeting CAR T cells | Drug Info | Phase 1/2 | leukaemia | [50] |
49 | CAR-T cells targeting CD19 | Drug Info | Phase 1/2 | leukaemia | [51] |
50 | CARCIK-CD19 | Drug Info | Phase 1/2 | Acute lymphocytic leukaemia | [52] |
51 | CART-19 cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [53] |
52 | CART-19/22 | Drug Info | Phase 1/2 | leukaemia | [54] |
53 | CART-19/BCMA | Drug Info | Phase 1/2 | Multiple myeloma | [55] |
54 | CD19 and CD20 CAR-T Cells | Drug Info | Phase 1/2 | B-cell lymphoma | [56] |
55 | CD19 and CD22 CAR-T Cells | Drug Info | Phase 1/2 | Lymphoma | [57] |
56 | CD19 and CD22 CAR-T Cells | Drug Info | Phase 1/2 | B-cell lymphoma | [56] |
57 | CD19 CAR Gene Transduced T Lymphocytes | Drug Info | Phase 1/2 | Non-hodgkin lymphoma | [58] |
58 | CD19 CAR T Cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [59] |
59 | CD19 CAR T cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [60] |
60 | CD19 CAR-T Cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [61] |
61 | CD19 CAR-T lymphocytes | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [62] |
62 | CD19 CART | Drug Info | Phase 1/2 | B-cell lymphoma | [63] |
63 | CD19 CART | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [64] |
64 | CD19 specific CAR T cells | Drug Info | Phase 1/2 | Acute leukaemia | [65] |
65 | CD19 targeted chimeric antigen receptor T cells | Drug Info | Phase 1/2 | B-cell lymphoma | [66] |
66 | CD19-CAR T cell | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [67] |
67 | CD19-directed CAR-T cells | Drug Info | Phase 1/2 | leukaemia | [68] |
68 | CD19-targeting CAR T Cells | Drug Info | Phase 1/2 | B-cell lymphoma | [69] |
69 | CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells | Drug Info | Phase 1/2 | Haematopoietic/lymphoid cancer | [70] |
70 | CD19.CAR T Cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [71] |
71 | CD19.CAR-T cells | Drug Info | Phase 1/2 | Diffuse large B-cell lymphoma | [72] |
72 | Chimeric Antigen Receptor Modified T cells Targeting CD19 | Drug Info | Phase 1/2 | leukaemia | [73] |
73 | CLIC-1901 | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [74] |
74 | Humanized CD19 CAR-T cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [75] |
75 | IM19 CAR-T | Drug Info | Phase 1/2 | leukaemia | [76], [77] |
76 | JCAR014 | Drug Info | Phase 1/2 | Non-hodgkin lymphoma | [78] |
77 | JCAR017 | Drug Info | Phase 1/2 | leukaemia | [79] |
78 | JCAR017 | Drug Info | Phase 1/2 | Chronic lymphocytic leukaemia | [80], [81] |
79 | KTE-C19 CAR | Drug Info | Phase 1/2 | Diffuse large B-cell lymphoma | [82] |
80 | PBCAR0191 | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [83] |
81 | PCAR-019 (anti-CD19 CAR-T cells) | Drug Info | Phase 1/2 | Acute lymphocytic leukaemia | [84] |
82 | SCRI-huCAR19v1 | Drug Info | Phase 1/2 | leukaemia | [85] |
83 | SJCAR19 | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [86] |
84 | TBI-1501 | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [87] |
85 | TriCAR-T-CD19 | Drug Info | Phase 1/2 | Non-hodgkin lymphoma | [88] |
86 | UCART019 | Drug Info | Phase 1/2 | B-cell lymphoma | [89] |
87 | 19-28z T CELLS | Drug Info | Phase 1 | Non-hodgkin lymphoma | [90] |
88 | 4SCAR19 cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [91] |
89 | AFM-11 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [92], [8] |
90 | Allogeneic CART-19 | Drug Info | Phase 1 | leukaemia | [93] |
91 | Anti-CD19 anti-CD20 Bispecific CAR-T | Drug Info | Phase 1 | leukaemia | [94] |
92 | Anti-CD19 CAR-T | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [95] |
93 | Anti-CD19 CAR-T cells | Drug Info | Phase 1 | leukaemia | [96] |
94 | Anti-CD19 CART Cells | Drug Info | Phase 1 | Multiple myeloma | [97] |
95 | Anti-CD19- CAR | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [98] |
96 | Anti-CD19-CAR T | Drug Info | Phase 1 | leukaemia | [99] |
97 | Anti-CD19-CAR T cells | Drug Info | Phase 1 | B-cell lymphoma | [100] |
98 | Anti-CD19/BCMA CAR-T cells | Drug Info | Phase 1 | Multiple myeloma | [101] |
99 | AntiCD19 CART | Drug Info | Phase 1 | Non-hodgkin lymphoma | [102] |
100 | ARI-0001 cells | Drug Info | Phase 1 | leukaemia | [103] |
101 | BCMA CART and huCART19 | Drug Info | Phase 1 | Multiple myeloma | [104] |
102 | C-CAR011 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [105], [106] |
103 | CAR-20/19-T Cells | Drug Info | Phase 1 | B-cell non-hodgkin lymphoma | [107] |
104 | CAR-T cells targeting CD19 | Drug Info | Phase 1 | Lymphoma | [108] |
105 | CAR-T Cells targeting CD19 | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [109] |
106 | CAR19 T cells carrying cytoplasmic activated PD-1 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [110] |
107 | CART-19 | Drug Info | Phase 1 | B-cell lymphoma | [111] |
108 | CART-19 | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [112] |
109 | CART-19 autologous T-cells | Drug Info | Phase 1 | Lymphoma | [113] |
110 | CART-19 cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [114] |
111 | CART-19 cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [115] |
112 | CART-19 T cells | Drug Info | Phase 1 | Multiple myeloma | [116] |
113 | CART-meso-19 T cells | Drug Info | Phase 1 | Pancreatic cancer | [117] |
114 | CART19 cell | Drug Info | Phase 1 | B-cell prolymphocytic leukaemia | [118] |
115 | CART22-65s cells and huCART19 Cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [119] |
116 | CARTmeso/19 | Drug Info | Phase 1 | Pancreatic cancer | [120] |
117 | CD19 CAR T | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [121] |
118 | CD19 CAR T Cells | Drug Info | Phase 1 | Acute lymphocytic leukaemia | [122] |
119 | CD19 CAR T cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [123] |
120 | CD19 CAR T-cells | Drug Info | Phase 1 | Non-hodgkin lymphoma | [124] |
121 | CD19 CAR T-cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [125] |
122 | CD19 CAR-T cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [126] |
123 | CD19 CAR-T cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [127] |
124 | CD19 Redirected Autologous T Cells | Drug Info | Phase 1 | Systemic lupus erythematosus | [128] |
125 | CD19+ CAR T Cells | Drug Info | Phase 1 | leukaemia | [129] |
126 | CD19-CAR and CD28-CAR T Cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [130] |
127 | CD19-CAR-T Cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [131] |
128 | CD19-CAR-T2 Cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [132] |
129 | CD19-directed CAR-T cells | Drug Info | Phase 1 | Non-hodgkin lymphoma | [133] |
130 | CD19-directed CAR-T cells | Drug Info | Phase 1 | leukaemia | [134] |
131 | CD19-targeted CART cells | Drug Info | Phase 1 | leukaemia | [135] |
132 | CD19-TriCAR-T | Drug Info | Phase 1 | Non-hodgkin lymphoma | [136] |
133 | CD19.CAR-aNKT cells | Drug Info | Phase 1 | B-cell small lymphocytic lymphoma | [137] |
134 | CD19/CD22 CAR T cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [138] |
135 | CD19/CD22 CAR T-Cells | Drug Info | Phase 1 | Acute lymphocytic leukaemia | [139] |
136 | CD19/CD22 Chimeric Antigen Receptor T Cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [140] |
137 | CD19CAT-41BBZ CAR T-cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [141] |
138 | Combotox | Drug Info | Phase 1 | leukaemia | [142] |
139 | Donor-derived CD19/22 bispecific CAR-T cells | Drug Info | Phase 1 | leukaemia | [134] |
140 | Dual Specificity CD19 and CD22 CAR-T Cell | Drug Info | Phase 1 | B-cell lymphoma | [143] |
141 | Duvortuxizumab | Drug Info | Phase 1 | B-cell lymphoma | [9] |
142 | EGFRt/19-28z/4-1BBL CAR T cells | Drug Info | Phase 1 | Chronic lymphocytic leukaemia | [144] |
143 | HuCART19 | Drug Info | Phase 1 | leukaemia | [145] |
144 | Human CD19 targeted T Cells | Drug Info | Phase 1 | Follicular lymphoma | [146] |
145 | IC9-CAR19 cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [147], [148] |
146 | IC9-CAR19 T cells | Drug Info | Phase 1 | B-cell lymphoma | [149] |
147 | ICAR19 CAR-T cells | Drug Info | Phase 1 | B-cell lymphoma | [150] |
148 | IM19 | Drug Info | Phase 1 | Haematological malignancy | [151] |
149 | JCAR014 | Drug Info | Phase 1 | B-cell lymphoma | [152] |
150 | JWCAR029 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [153] |
151 | JWCAR029 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [154] |
152 | MEDl-551 | Drug Info | Phase 1 | Scleroderma | [155] |
153 | Patient-derived CD19- and CD22 specific CAR | Drug Info | Phase 1 | leukaemia | [156] |
154 | PZ01 CAR-T cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [157] |
155 | Anti-CD19 Chimeric Antigen Receptor T Cells | Drug Info | Clinical trial | leukaemia | [158] |
156 | Anti-CD19/20-CAR vector-transduced T cells | Drug Info | Clinical trial | Acute lymphoblastic leukaemia | [159] |
157 | CAR-CD19 T cell | Drug Info | Clinical trial | B-cell lymphoma | [160] |
158 | CD19-CAR T Cells | Drug Info | Clinical trial | Acute lymphoblastic leukaemia | [161] |
159 | CD19-targeted CAR-T cells | Drug Info | Clinical trial | leukaemia | [162] |
160 | CD19-targeted CAR-T cells | Drug Info | Clinical trial | leukaemia | [163] |
161 | CD19-UCART | Drug Info | Clinical trial | Acute lymphoblastic leukaemia | [164] |
162 | CD19CART | Drug Info | Clinical trial | B-cell lymphoma | [165] |
Preclinical Drug(s) | [+] 3 Preclinical Drugs | + | |||
1 | Anti-CD19 CAR T cells | Drug Info | Phase 0 | Hodgkin lymphoma | [166] |
2 | CART19 cells | Drug Info | Phase 0 | Hodgkin lymphoma | [167] |
3 | SGN-19A | Drug Info | Preclinical | Haematological malignancy | [168] |
Mode of Action | [+] 5 Modes of Action | + | |||
Immunostimulant | [+] 2 Immunostimulant drugs | + | |||
1 | Axicabtagene ciloleucel | Drug Info | [2] | ||
2 | Tisagenlecleucel | Drug Info | [2] | ||
Modulator | [+] 9 Modulator drugs | + | |||
1 | Blinatumomab | Drug Info | [1] | ||
2 | CTL019 | Drug Info | [171] | ||
3 | JCAR015 | Drug Info | [172] | ||
4 | Xmab 5871 | Drug Info | [176], [177] | ||
5 | JCAR014 | Drug Info | [172] | ||
6 | JCAR017 | Drug Info | [172] | ||
7 | AFM-11 | Drug Info | [177] | ||
8 | Combotox | Drug Info | [188] | ||
9 | Anti-CD22/CD19 mab-toxin conjugate | Drug Info | [193] | ||
CAR-T-Cell-Therapy | [+] 116 CAR-T-Cell-Therapy drugs | + | |||
1 | CART-19 | Drug Info | [5] | ||
2 | CD19 CAR T cells | Drug Info | [6], [169] | ||
3 | CAR-T cells targeting CD19 | Drug Info | [10] | ||
4 | CART 19 | Drug Info | [11], [12], [170] | ||
5 | CD19 CAR T cells | Drug Info | [15] | ||
6 | CTL019 | Drug Info | [18], [19] | ||
7 | JCAR015 | Drug Info | [21] | ||
8 | KYMRIAH | Drug Info | [23] | ||
9 | MB-CART19.1 | Drug Info | [24] | ||
10 | TBI-1501 | Drug Info | [87] | ||
11 | XLCART001 | Drug Info | [27] | ||
12 | YESCARTA | Drug Info | [23] | ||
13 | 4SCAR19 cells | Drug Info | [30] | ||
14 | Anti-CD19 CAR T cells | Drug Info | [33], [34] | ||
15 | Anti-CD19 CAR transduced T cells | Drug Info | [35] | ||
16 | Anti-CD19 CAR-T | Drug Info | [36] | ||
17 | Anti-CD19 CAR-T cells | Drug Info | [37] | ||
18 | Anti-CD19 CAR-T cells | Drug Info | [38] | ||
19 | Anti-CD19 CAR-T cells | Drug Info | [39], [40] | ||
20 | Anti-CD19 CAR-T cells | Drug Info | [41] | ||
21 | Anti-CD19-CAR PBL | Drug Info | [42] | ||
22 | Anti-CD19-CAR vector-transduced T cells | Drug Info | [43], [44] | ||
23 | Anti-CD19-CAR-T cells | Drug Info | [45] | ||
24 | Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Drug Info | [49] | ||
25 | Autologous CD19-targeting CAR T cells | Drug Info | [50] | ||
26 | CAR-T cells targeting CD19 | Drug Info | [51] | ||
27 | CARCIK-CD19 | Drug Info | [52] | ||
28 | CART-19 cells | Drug Info | [53] | ||
29 | CD19 CAR Gene Transduced T Lymphocytes | Drug Info | [58] | ||
30 | CD19 CAR T Cells | Drug Info | [59] | ||
31 | CD19 CAR T cells | Drug Info | [60] | ||
32 | CD19 CAR-T Cells | Drug Info | [61] | ||
33 | CD19 CAR-T lymphocytes | Drug Info | [62] | ||
34 | CD19 CART | Drug Info | [63] | ||
35 | CD19 CART | Drug Info | [64] | ||
36 | CD19 specific CAR T cells | Drug Info | [65] | ||
37 | CD19 targeted chimeric antigen receptor T cells | Drug Info | [66] | ||
38 | CD19-CAR T cell | Drug Info | [67] | ||
39 | CD19-directed CAR-T cells | Drug Info | [68] | ||
40 | CD19-targeting CAR T cells | Drug Info | [16], [17] | ||
41 | CD19-targeting CAR T Cells | Drug Info | [69] | ||
42 | CD19.CAR T Cells | Drug Info | [71] | ||
43 | CD19.CAR-T cells | Drug Info | [72] | ||
44 | Chimeric Antigen Receptor Modified T cells Targeting CD19 | Drug Info | [73] | ||
45 | CLIC-1901 | Drug Info | [74] | ||
46 | Humanized CD19 CAR-T cells | Drug Info | [75] | ||
47 | IM19 CAR-T | Drug Info | [76], [77] | ||
48 | JCAR017 | Drug Info | [22], [179], [180] | ||
49 | PBCAR0191 | Drug Info | [83] | ||
50 | PCAR-019 (anti-CD19 CAR-T cells) | Drug Info | [84] | ||
51 | SCRI-huCAR19v1 | Drug Info | [85] | ||
52 | SJCAR19 | Drug Info | [86] | ||
53 | TriCAR-T-CD19 | Drug Info | [88] | ||
54 | UCART019 | Drug Info | [89] | ||
55 | 19-28z T CELLS | Drug Info | [90] | ||
56 | 4SCAR19 cells | Drug Info | [91] | ||
57 | Allogeneic CART-19 | Drug Info | [93] | ||
58 | Anti-CD19 CAR-T | Drug Info | [95] | ||
59 | Anti-CD19 CAR-T cells | Drug Info | [96] | ||
60 | Anti-CD19 CART Cells | Drug Info | [97] | ||
61 | Anti-CD19- CAR | Drug Info | [98] | ||
62 | Anti-CD19-CAR T | Drug Info | [99] | ||
63 | Anti-CD19-CAR T cells | Drug Info | [100] | ||
64 | AntiCD19 CART | Drug Info | [102] | ||
65 | ARI-0001 cells | Drug Info | [103] | ||
66 | C-CAR011 | Drug Info | [105], [106] | ||
67 | CAR-T cells targeting CD19 | Drug Info | [108] | ||
68 | CAR-T Cells targeting CD19 | Drug Info | [109] | ||
69 | CAR19 T cells carrying cytoplasmic activated PD-1 | Drug Info | [110] | ||
70 | CART-19 | Drug Info | [13], [182], [183], [184], [185] | ||
71 | CART-19 | Drug Info | [111] | ||
72 | CART-19 | Drug Info | [112] | ||
73 | CART-19 autologous T-cells | Drug Info | [113] | ||
74 | CART-19 cells | Drug Info | [186], [14] | ||
75 | CART-19 cells | Drug Info | [114] | ||
76 | CART-19 cells | Drug Info | [115] | ||
77 | CART-19 T cells | Drug Info | [116] | ||
78 | CART19 cell | Drug Info | [118] | ||
79 | CD19 CAR T | Drug Info | [121] | ||
80 | CD19 CAR T Cells | Drug Info | [122] | ||
81 | CD19 CAR T cells | Drug Info | [123], [187] | ||
82 | CD19 CAR T-cells | Drug Info | [124] | ||
83 | CD19 CAR T-cells | Drug Info | [125] | ||
84 | CD19 CAR-T cells | Drug Info | [126] | ||
85 | CD19 CAR-T cells | Drug Info | [127] | ||
86 | CD19 Redirected Autologous T Cells | Drug Info | [128] | ||
87 | CD19+ CAR T Cells | Drug Info | [129] | ||
88 | CD19-CAR-T Cells | Drug Info | [131] | ||
89 | CD19-CAR-T2 Cells | Drug Info | [132] | ||
90 | CD19-directed CAR-T cells | Drug Info | [133] | ||
91 | CD19-directed CAR-T cells | Drug Info | [134] | ||
92 | CD19-targeted CART cells | Drug Info | [135] | ||
93 | CD19-TriCAR-T | Drug Info | [136] | ||
94 | CD19.CAR-aNKT cells | Drug Info | [137] | ||
95 | CD19CAT-41BBZ CAR T-cells | Drug Info | [141] | ||
96 | EGFRt/19-28z/4-1BBL CAR T cells | Drug Info | [144] | ||
97 | HuCART19 | Drug Info | [145] | ||
98 | Human CD19 targeted T Cells | Drug Info | [146] | ||
99 | IC9-CAR19 cells | Drug Info | [147], [148] | ||
100 | IC9-CAR19 T cells | Drug Info | [149] | ||
101 | ICAR19 CAR-T cells | Drug Info | [150] | ||
102 | IM19 | Drug Info | [189], [151] | ||
103 | JCAR014 | Drug Info | [152] | ||
104 | JCAR017 | Drug Info | [80], [190], [81] | ||
105 | JWCAR029 | Drug Info | [153] | ||
106 | JWCAR029 | Drug Info | [154] | ||
107 | PZ01 CAR-T cells | Drug Info | [157] | ||
108 | Anti-CD19 Chimeric Antigen Receptor T Cells | Drug Info | [158] | ||
109 | CAR-CD19 T cell | Drug Info | [160] | ||
110 | CD19-CAR T Cells | Drug Info | [161] | ||
111 | CD19-targeted CAR-T cells | Drug Info | [191], [192], [162] | ||
112 | CD19-targeted CAR-T cells | Drug Info | [163] | ||
113 | CD19-UCART | Drug Info | [164] | ||
114 | CD19CART | Drug Info | [165] | ||
115 | Anti-CD19 CAR T cells | Drug Info | [166] | ||
116 | CART19 cells | Drug Info | [167] | ||
Inhibitor | [+] 3 Inhibitor drugs | + | |||
1 | Coltuximab ravtansine | Drug Info | [9] | ||
2 | Inebilizumab | Drug Info | [20] | ||
3 | KTE-C19 CAR | Drug Info | [181] | ||
CAR-T-Cell-Therapy(Dual specific) | [+] 32 CAR-T-Cell-Therapy(Dual specific) drugs | + | |||
1 | 4SCAR19 and 4SCAR123 | Drug Info | [29] | ||
2 | 4SCAR19 and 4SCAR20 | Drug Info | [29] | ||
3 | 4SCAR19 and 4SCAR22 | Drug Info | [29] | ||
4 | 4SCAR19 and 4SCAR30 | Drug Info | [29] | ||
5 | 4SCAR19 and 4SCAR38 | Drug Info | [29] | ||
6 | 4SCAR19 and 4SCAR70 | Drug Info | [29] | ||
7 | 4SCAR19/22 T cells | Drug Info | [31] | ||
8 | Anti-CD19 and Anti-CD20 CAR-T Cells | Drug Info | [32] | ||
9 | Anti-CD19/22-CAR vector-transduced T cells | Drug Info | [46] | ||
10 | Anti-CD20 CAR-T cells | Drug Info | [47] | ||
11 | AUTO3 | Drug Info | [48], [178] | ||
12 | CART-19/22 | Drug Info | [54] | ||
13 | CART-19/BCMA | Drug Info | [55] | ||
14 | CD19 and CD20 CAR-T Cells | Drug Info | [56] | ||
15 | CD19 and CD22 CAR-T Cells | Drug Info | [57] | ||
16 | CD19 and CD22 CAR-T Cells | Drug Info | [56] | ||
17 | CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells | Drug Info | [70] | ||
18 | Anti-CD19 anti-CD20 Bispecific CAR-T | Drug Info | [94] | ||
19 | Anti-CD19/BCMA CAR-T cells | Drug Info | [101] | ||
20 | BCMA CART and huCART19 | Drug Info | [104] | ||
21 | CAR-20/19-T Cells | Drug Info | [107] | ||
22 | CART-meso-19 T cells | Drug Info | [117] | ||
23 | CART22-65s cells and huCART19 Cells | Drug Info | [119] | ||
24 | CARTmeso/19 | Drug Info | [120] | ||
25 | CD19-CAR and CD28-CAR T Cells | Drug Info | [130] | ||
26 | CD19/CD22 CAR T cells | Drug Info | [138] | ||
27 | CD19/CD22 CAR T-Cells | Drug Info | [139] | ||
28 | CD19/CD22 Chimeric Antigen Receptor T Cells | Drug Info | [140] | ||
29 | Donor-derived CD19/22 bispecific CAR-T cells | Drug Info | [134] | ||
30 | Dual Specificity CD19 and CD22 CAR-T Cell | Drug Info | [143] | ||
31 | Patient-derived CD19- and CD22 specific CAR | Drug Info | [156] | ||
32 | Anti-CD19/20-CAR vector-transduced T cells | Drug Info | [159] | ||
Target Regulators | |||||
Target-regulating Transcription Factors | |||||
Target-interacting Proteins | |||||
Target Profiles in Patients | |||||
Target Expression Profile (TEP) | |||||
Target Affiliated Biological Pathways | |||||
KEGG Pathway | [+] 5 KEGG Pathways | + | |||
1 | PI3K-Akt signaling pathway | ||||
2 | Hematopoietic cell lineage | ||||
3 | B cell receptor signaling pathway | ||||
4 | Epstein-Barr virus infection | ||||
5 | Primary immunodeficiency | ||||
NetPath Pathway | [+] 1 NetPath Pathways | + | |||
1 | IL-7 Signaling Pathway | ||||
Panther Pathway | [+] 1 Panther Pathways | + | |||
1 | B cell activation | ||||
PID Pathway | [+] 1 PID Pathways | + | |||
1 | BCR signaling pathway | ||||
Reactome | [+] 4 Reactome Pathways | + | |||
1 | PIP3 activates AKT signaling | ||||
2 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
3 | Constitutive Signaling by Aberrant PI3K in Cancer | ||||
4 | Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
WikiPathways | [+] 5 WikiPathways | + | |||
1 | Human Complement System | ||||
2 | Signaling by the B Cell Receptor (BCR) | ||||
3 | PIP3 activates AKT signaling | ||||
4 | B Cell Receptor Signaling Pathway | ||||
5 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
Target-Related Models and Studies | |||||
Target Validation | |||||
References | |||||
REF 1 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | ||||
REF 2 | 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. | ||||
REF 3 | ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | ||||
REF 4 | ClinicalTrials.gov (NCT02393859) Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL | ||||
REF 5 | ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL | ||||
REF 6 | ClinicalTrials.gov (NCT03391739) CART-19 Cells For R/R B-ALL | ||||
REF 7 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
REF 8 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
REF 9 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
REF 10 | ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL | ||||
REF 11 | ClinicalTrials.gov (NCT02935543) CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | ||||
REF 12 | ClinicalTrials.gov (NCT02906371) Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | ||||
REF 13 | ClinicalTrials.gov (NCT02030834) Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas | ||||
REF 14 | ClinicalTrials.gov (NCT02794246) CART-19 Post-ASCT for Multiple Myeloma | ||||
REF 15 | ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies | ||||
REF 16 | ClinicalTrials.gov (NCT02132624) CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. | ||||
REF 17 | ClinicalTrials.gov (NCT03068416) CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy | ||||
REF 18 | ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health. | ||||
REF 19 | ClinicalTrials.gov (NCT03601442) CTL019 Out of Specification MAP for ALL or DLBCL Patients | ||||
REF 20 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
REF 21 | ClinicalTrials.gov (NCT02535364) Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL). | ||||
REF 22 | ClinicalTrials.gov (NCT03484702) Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma | ||||
REF 23 | ClinicalTrials.gov (NCT03642626) MT2017-45 :CAR-T Cell Therapy for Heme Malignancies | ||||
REF 24 | ClinicalTrials.gov (NCT03321123) MB-CART19.1 in Patients With R/R ALL | ||||
REF 25 | ClinicalTrials.gov (NCT01974479) Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia. U.S. National Institutes of Health. | ||||
REF 26 | A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014 Jan 1;20(1):213-20. | ||||
REF 27 | ClinicalTrials.gov (NCT03598179) XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects | ||||
REF 28 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035125) | ||||
REF 29 | ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies | ||||
REF 30 | ClinicalTrials.gov (NCT03050190) A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies | ||||
REF 31 | ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies | ||||
REF 32 | ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma | ||||
REF 33 | ClinicalTrials.gov (NCT02842138) Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma | ||||
REF 34 | ClinicalTrials.gov (NCT02247609) Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas | ||||
REF 35 | ClinicalTrials.gov (NCT03191773) A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | ||||
REF 36 | ClinicalTrials.gov (NCT02685670) Competitive Transfer of CD19-TCRz-CD28 and CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma | ||||
REF 37 | ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | ||||
REF 38 | ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | ||||
REF 39 | ClinicalTrials.gov (NCT03366324) Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | ||||
REF 40 | ClinicalTrials.gov (NCT03366350) Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | ||||
REF 41 | ClinicalTrials.gov (NCT02782351) Humanized CAR-T Therapy for Treatment of B Cell Malignancy | ||||
REF 42 | ClinicalTrials.gov (NCT00924326) CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | ||||
REF 43 | ClinicalTrials.gov (NCT02081937) CART-19 Immunotherapy in Mantle Cell Lymphoma | ||||
REF 44 | ClinicalTrials.gov (NCT01864889) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 | ||||
REF 45 | ClinicalTrials.gov (NCT02672501) A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia | ||||
REF 46 | ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | ||||
REF 47 | ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) | ||||
REF 48 | ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL | ||||
REF 49 | ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia | ||||
REF 50 | ClinicalTrials.gov (NCT02963038) CAR T Cells for Refractory B Cell Malignancy | ||||
REF 51 | ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | ||||
REF 52 | ClinicalTrials.gov (NCT03389035) Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT | ||||
REF 53 | ClinicalTrials.gov (NCT03544021) CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia ALL | ||||
REF 54 | ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | ||||
REF 55 | ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT | ||||
REF 56 | ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma | ||||
REF 57 | ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma | ||||
REF 58 | ClinicalTrials.gov (NCT02134262) Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes | ||||
REF 59 | ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | ||||
REF 60 | ClinicalTrials.gov (NCT02772198) T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | ||||
REF 61 | ClinicalTrials.gov (NCT03263208) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | ||||
REF 62 | ClinicalTrials.gov (NCT03467256) CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | ||||
REF 63 | ClinicalTrials.gov (NCT03146533) CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. | ||||
REF 64 | ClinicalTrials.gov (NCT03232619) CD19-CART Treatment for ALL | ||||
REF 65 | ClinicalTrials.gov (NCT02028455) A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia | ||||
REF 66 | ClinicalTrials.gov (NCT03118180) CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma | ||||
REF 67 | ClinicalTrials.gov (NCT03373071) Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL | ||||
REF 68 | ClinicalTrials.gov (NCT02537977) CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy | ||||
REF 69 | ClinicalTrials.gov (NCT02547948) CD19-targeting CAR T Cells for B Cell Lymphoma | ||||
REF 70 | ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy | ||||
REF 71 | ClinicalTrials.gov (NCT03676504) Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | ||||
REF 72 | ClinicalTrials.gov (NCT02652910) Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma | ||||
REF 73 | ClinicalTrials.gov (NCT02349698) A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | ||||
REF 74 | ClinicalTrials.gov (NCT03765177) CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies | ||||
REF 75 | ClinicalTrials.gov (NCT03275493) Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | ||||
REF 76 | ClinicalTrials.gov (NCT03142646) Safety and Efficacy Evaluation of IM19 CAR-T Cells | ||||
REF 77 | ClinicalTrials.gov (NCT03173417) Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T) | ||||
REF 78 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041075) | ||||
REF 79 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041076) | ||||
REF 80 | ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | ||||
REF 81 | ClinicalTrials.gov (NCT03331198) Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | ||||
REF 82 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039436) | ||||
REF 83 | ClinicalTrials.gov (NCT03666000) Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL | ||||
REF 84 | ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | ||||
REF 85 | ClinicalTrials.gov (NCT03684889) CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma | ||||
REF 86 | ClinicalTrials.gov (NCT03573700) Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia | ||||
REF 87 | ClinicalTrials.gov (NCT03155191) Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia | ||||
REF 88 | ClinicalTrials.gov (NCT03497533) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 | ||||
REF 89 | ClinicalTrials.gov (NCT03166878) A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | ||||
REF 90 | ClinicalTrials.gov (NCT01840566) High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma | ||||
REF 91 | ClinicalTrials.gov (NCT02968472) A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia | ||||
REF 92 | ClinicalTrials.gov (NCT02106091) Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL or B-precursor ALL. U.S. National Institutes of Health. | ||||
REF 93 | ClinicalTrials.gov (NCT02799550) Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL | ||||
REF 94 | ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL | ||||
REF 95 | ClinicalTrials.gov (NCT03110640) Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | ||||
REF 96 | ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | ||||
REF 97 | ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | ||||
REF 98 | ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | ||||
REF 99 | ClinicalTrials.gov (NCT02546739) Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL | ||||
REF 100 | ClinicalTrials.gov (NCT02659943) T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies | ||||
REF 101 | ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | ||||
REF 102 | ClinicalTrials.gov (NCT03434769) AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma | ||||
REF 103 | ClinicalTrials.gov (NCT03144583) Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy | ||||
REF 104 | ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma | ||||
REF 105 | ClinicalTrials.gov (NCT03299738) A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL | ||||
REF 106 | ClinicalTrials.gov (NCT03154775) Study of Safety and Efficacy of C-CAR011 in B-NHL Patients | ||||
REF 107 | ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells | ||||
REF 108 | ClinicalTrials.gov (NCT03086954) Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma | ||||
REF 109 | ClinicalTrials.gov (NCT03186118) Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia | ||||
REF 110 | ClinicalTrials.gov (NCT03540303) Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma | ||||
REF 111 | ClinicalTrials.gov (NCT03101709) The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma | ||||
REF 112 | ClinicalTrials.gov (NCT02810223) Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | ||||
REF 113 | ClinicalTrials.gov (NCT02476734) FDG-PET/CT Imaging as Early Predictor of DP | ||||
REF 114 | ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | ||||
REF 115 | ClinicalTrials.gov (NCT02924753) The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). | ||||
REF 116 | ClinicalTrials.gov (NCT02135406) CART-19 for Multiple Myeloma | ||||
REF 117 | ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | ||||
REF 118 | ClinicalTrials.gov (NCT03685786) CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT | ||||
REF 119 | ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL | ||||
REF 120 | ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer | ||||
REF 121 | ClinicalTrials.gov (NCT03559439) CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies | ||||
REF 122 | ClinicalTrials.gov (NCT01853631) Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | ||||
REF 123 | ClinicalTrials.gov (NCT02975687) CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia | ||||
REF 124 | ClinicalTrials.gov (NCT03298828) CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | ||||
REF 125 | ClinicalTrials.gov (NCT02443831) CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies | ||||
REF 126 | ClinicalTrials.gov (NCT03671460) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | ||||
REF 127 | ClinicalTrials.gov (NCT03064269) CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia | ||||
REF 128 | ClinicalTrials.gov (NCT03030976) A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) | ||||
REF 129 | ClinicalTrials.gov (NCT02529813) CD19+ CAR T Cells for Lymphoid Malignancies | ||||
REF 130 | ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia | ||||
REF 131 | ClinicalTrials.gov (NCT03574168) CD19-CAR-T Cells in Patients With R/R B-ALL | ||||
REF 132 | ClinicalTrials.gov (NCT02822326) Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia | ||||
REF 133 | ClinicalTrials.gov (NCT03483688) A Phaseb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects | ||||
REF 134 | ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia | ||||
REF 135 | ClinicalTrials.gov (NCT03599375) Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia | ||||
REF 136 | ClinicalTrials.gov (NCT03720496) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCAR-T Cell Therapy | ||||
REF 137 | ClinicalTrials.gov (NCT03774654) CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | ||||
REF 138 | ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia | ||||
REF 139 | ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | ||||
REF 140 | ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia | ||||
REF 141 | ClinicalTrials.gov (NCT02935257) Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia Using CAR T-cells to Target CD19 | ||||
REF 142 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027936) | ||||
REF 143 | ClinicalTrials.gov (NCT03593109) Safety and Efficacy Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in Relapsed or Refractory Lymphoma | ||||
REF 144 | ClinicalTrials.gov (NCT03085173) A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | ||||
REF 145 | ClinicalTrials.gov (NCT02374333) Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy | ||||
REF 146 | ClinicalTrials.gov (NCT03720457) Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | ||||
REF 147 | ClinicalTrials.gov (NCT03016377) Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia | ||||
REF 148 | ClinicalTrials.gov (NCT03594162) Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch | ||||
REF 149 | ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | ||||
REF 150 | ClinicalTrials.gov (NCT03383952) A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia | ||||
REF 151 | ClinicalTrials.gov (NCT03344705) Safety and Efficacy Evaluation of IM19 Cells | ||||
REF 152 | ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | ||||
REF 153 | ClinicalTrials.gov (NCT03344367) Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | ||||
REF 154 | ClinicalTrials.gov (NCT03355859) Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | ||||
REF 155 | CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7. | ||||
REF 156 | ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma | ||||
REF 157 | ClinicalTrials.gov (NCT03281551) Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma | ||||
REF 158 | ClinicalTrials.gov (NCT03624686) Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies | ||||
REF 159 | ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | ||||
REF 160 | ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | ||||
REF 161 | ClinicalTrials.gov (NCT03423706) Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation | ||||
REF 162 | ClinicalTrials.gov (NCT02735291) Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia | ||||
REF 163 | ClinicalTrials.gov (NCT03564977) CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation | ||||
REF 164 | ClinicalTrials.gov (NCT03229876) Safety and Efficacy Evaluation of CD19-UCART | ||||
REF 165 | ClinicalTrials.gov (NCT02813837) Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies | ||||
REF 166 | ClinicalTrials.gov (NCT02277522) CD19 Redirected Autologous T Cells for Hodgkin Lymphoma | ||||
REF 167 | ClinicalTrials.gov (NCT02624258) Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma | ||||
REF 168 | 2011 Pipeline of Seattle Genetics. | ||||
REF 169 | ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma | ||||
REF 170 | ClinicalTrials.gov (NCT02640209) Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | ||||
REF 171 | Clinical pipeline report, company report or official report of Novartis. | ||||
REF 172 | Clinical pipeline report, company report or official report of JUNO Therapeutics. | ||||
REF 173 | A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010 Feb;59(2):257-65. | ||||
REF 174 | Clinical pipeline report, company report or official report of MedImmune (2011). | ||||
REF 175 | A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. | ||||
REF 176 | Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64. | ||||
REF 177 | Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. | ||||
REF 178 | ClinicalTrials.gov (NCT03287817) CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma | ||||
REF 179 | ClinicalTrials.gov (NCT03310619) A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) | ||||
REF 180 | ClinicalTrials.gov (NCT03743246) A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | ||||
REF 181 | Clinical pipeline report, company report or official report of Kite Pharma. | ||||
REF 182 | ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | ||||
REF 183 | ClinicalTrials.gov (NCT01747486) CD19 Redirected Autologous T Cells | ||||
REF 184 | ClinicalTrials.gov (NCT01626495) Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma | ||||
REF 185 | ClinicalTrials.gov (NCT02030847) Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia | ||||
REF 186 | ClinicalTrials.gov (NCT01551043) Allo CART-19 Protocol | ||||
REF 187 | ClinicalTrials.gov (NCT03029338) CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma | ||||
REF 188 | A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6. | ||||
REF 189 | ClinicalTrials.gov (NCT03528421) Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients | ||||
REF 190 | ClinicalTrials.gov (NCT02631044) Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | ||||
REF 191 | ClinicalTrials.gov (NCT02728882) Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma | ||||
REF 192 | ClinicalTrials.gov (NCT03488160) CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma | ||||
REF 193 | Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.